- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02451969
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
May 1, 2017 updated by: Sinovac Biotech Co., Ltd
Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly
The purpose of this study is to evaluate the immunogenicity and safety of an investigational 23-valent pneumococcal polysaccharide vaccine (PPV) in healthy children, adults and elderly.
The control vaccine is a commercialized 23-valent PPV.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized, double-blind, single-center, controlled phase III clinical trial.
The purpose of this study is to evaluate the immunogenicity and safety of an investigational 23-valent pneumococcal polysaccharide vaccine (PPV) manufactured by Sinovac Biotech Co., Ltd.
The primary objective of this study is to demonstrate that the immunogenicity of the investigational vaccine is non-inferior to that of a commercialized 23-valent PPV manufactured by Chengdu Institute of Biological products Co., Ltd.; the secondary objective is to assess the safety of the investigational and control vaccines.
Participants will be grouped into three cohorts by age: child cohort (2 - 17 years old), adult cohort (18 - 60 years old) and elderly cohort (≥ 61 years old).
In each cohort, the participants will be randomly assigned into experimental group or control group in the ratio 1:1.
Study Type
Interventional
Enrollment (Actual)
1760
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Henan
-
Kaifeng, Henan, China, 475100
- Kaifeng County Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteer ≥ 2 years old;
- Proven legal identity;
- Written consent of the guardian of participants < 18 years old, and written consent of the participant ≥ 12 years old;
- Complying with the requirement of the study protocol;
Exclusion Criteria:
- Prior vaccination with pneumococcal vaccine;
- History of bacterial pneumonia within 3 years prior to this study;
- Pregnant, breast feeding, or women expected to conceive within 60 days after vaccination;
- History of allergy to any vaccine or vaccine ingredient;
Receipt of any of the following products:
- Blood product within 3 months prior to study entry;
- Any live attenuated vaccine within 28 days prior to study entry;
- Any subunit vaccine or inactivated vaccine within 14 days prior to study entry;
- Any immunosuppressant within 6 month prior to study entry;
- Congenital malformation, developmental disorders, serious chronic diseases, autoimmune disease, immunodeficiency, serious cardiovascular disease, diabetes, hypertension that cannot be stabilized by medication, liver or kidney disease, or malignant tumor;
- History of asthma, thyroidectomy, angioneurotic edema, severe nervous system disease or mental illness; without spleen or splenectomy; diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities), or obvious bruising or coagulation disorders;
- Acute disease or acute stage of chronic disease within 7 days prior to study entry;
- Axillaty temperature > 37.0 °C;
- Any other factor that in the opinion of the investigator suggesting the volunteer is unsuitable for this study;
Participants with the following conditions from day 0 - 28 would be included in the full analysis set (FAS), but would be excluded from the per protocol set (PPS):
- Receipt of any other investigational or unregistered product (drug or vaccine);
- Receipt of immunosuppressant (corticosteroid dosage that equivalent to or above 0.5 mg prednisone/kg weight/day) for > 14 days, except for inhalant or locally administrated corticosteroid;
- Receipt of immunoglobulin and/or blood product;
- Newly diagnosed autoimmune disease or immunodeficiency (e.g., HIV infection);
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
|
The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
|
Active Comparator: Control Group
|
The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The seroconversion rates (SCR) of each of the 23 pneumococcal serotypes
Time Frame: 28 days
|
For each serotype, the SCR is the percentage of participants with the increase of relative antibody concentration ≥ 2 folds after vaccination.
The relative antibody concentrations were measured using Enzyme Linked Immunosorbent Assay (ELISA).
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidences of adverse events (AEs)
Time Frame: 28 days
|
After each injection, a 30-minute safety observation was conducted immediately.
The body temperature, occurrence of solicited local and general AEs on day 0 - 7 were reported.
Unsolicited AEs occurred during day 0 - 28 were also reported.
Each AE case was reviewed by the investigator to determine whether or not it was an adverse reaction (related to the vaccination).
|
28 days
|
The increases of relative antibody concentration against each of the 23 pneumococcal serotypes
Time Frame: 28 days
|
The relative antibody concentrations in the pre- and post-immunization serum samples were measured using ELISA.
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Weiping Ru, BS, Henan Provincial Center for Disease Control and Prevention
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
February 1, 2017
Study Registration Dates
First Submitted
May 20, 2015
First Submitted That Met QC Criteria
May 20, 2015
First Posted (Estimate)
May 22, 2015
Study Record Updates
Last Update Posted (Actual)
May 3, 2017
Last Update Submitted That Met QC Criteria
May 1, 2017
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-PPV-3001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumococcal Infections
-
Johns Hopkins Bloomberg School of Public HealthPfizer; National Institutes of Health (NIH); Centers for Disease Control and...CompletedInvasive Pneumococcal Disease | Pneumococcal Nasopharyngeal ColonizationUnited States
-
Institut National de la Santé Et de la Recherche...CompletedPneumococcal DiseasesFrance
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedInvasive Pneumococcal DiseaseIceland
-
GlaxoSmithKlineCompletedProphylactic Pneumococcal DiseasesBelgium
-
Centers for Disease Control and PreventionKaiser PermanenteCompletedPneumococcal Disease PreventionUnited States
-
PfizerCompletedPneumococcal Disease | 13-valent Pneumococcal VaccineUnited States
-
Walvax Biotechnology Co., Ltd.Enrolling by invitationPneumococcal Disease, InvasiveIndonesia
-
PfizerCompletedInvasive Pneumococcal DiseaseSpain
-
PfizerKaiser PermanenteCompletedInvasive Pneumococcal DiseaseUnited States
-
PfizerCompletedPneumococcal DiseasesTurkey
Clinical Trials on investigational 23-valent PPV
-
Sinovac Biotech Co., LtdCompleted
-
Sinovac Biotech Co., LtdCompletedPneumococcal InfectionsChina
-
WestatEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPNC Vaccine | HIV-infected Pregnant WomenBrazil
-
Sinovac Biotech Co., LtdCompletedPneumococcal InfectionsChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
Novartis PharmaceuticalsRecruitingRelapsing Multiple SclerosisUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Poland, Portugal, Russian Federation, Slovakia, Spain, Denmark, France, Japan, Israel, Taiwan, Turkey, Czechia, Argentina, Estonia, United Kingdom, India, C... and more
-
VA Office of Research and DevelopmentTerminatedAging | Renal TransplantationUnited States
-
Seema BhatRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
PATHCompleted
-
University of UtahNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States